Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGbeta conjugate: functional characteristic and molecular mechanism of cell death pathway
- PMID: 15956772
- DOI: 10.1177/15353702-0323006-10
Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGbeta conjugate: functional characteristic and molecular mechanism of cell death pathway
Abstract
A Hecate-CGbeta conjugate (lytic peptide and beta-chorionic gonadotropin) selectively destroyed cells possessing LH receptors. This study described functional characteristics of the conjugate and the molecular mechanism of the cell death pathway in prostate cancer cells. Based on in vitro studies, we conclude that the conjugate kills cells possessing luteinizing hormone receptors (LHR) faster than Hecate alone. Competitive studies have shown that blocking of LHR by preincubation with chorionic gonadotropin (100 ng/ml) reduced toxicity of the conjugate in low concentrations. Further studies have also shown that the conjugate in treated cells both did not induce internucleosomal DNA fragmentation and did not induce morphological changes in cells characterized as having apoptotic features. These results proved that cells died by necrosis rather than apoptosis after the conjugate treatment.
Similar articles
-
Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin beta conjugate.Endocr Relat Cancer. 2008 Jun;15(2):635-48. doi: 10.1677/ERC-08-0015. Endocr Relat Cancer. 2008. PMID: 18509010
-
A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate.Breast Cancer Res Treat. 2003 May;79(1):1-10. doi: 10.1023/a:1023351819956. Breast Cancer Res Treat. 2003. PMID: 12779076
-
A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice.Neoplasia. 2005 May;7(5):497-508. doi: 10.1593/neo.04751. Neoplasia. 2005. PMID: 15967102 Free PMC article.
-
Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors.Mol Cell Endocrinol. 2007 Apr 15;269(1-2):17-25. doi: 10.1016/j.mce.2006.11.016. Epub 2007 Feb 12. Mol Cell Endocrinol. 2007. PMID: 17363137 Review.
-
Targeting breast and prostate cancers through their hormone receptors.Biol Reprod. 2005 Nov;73(5):860-5. doi: 10.1095/biolreprod.105.043471. Epub 2005 Jul 20. Biol Reprod. 2005. PMID: 16033998 Review.
Cited by
-
"Been hit twice": a novel bi-allelic heterozygous mutation in LHCGR.J Assist Reprod Genet. 2014 Jul;31(7):783-6. doi: 10.1007/s10815-014-0284-2. J Assist Reprod Genet. 2014. PMID: 24974358 Free PMC article. No abstract available.
-
Melittin Increases Cisplatin Sensitivity and Kills KM-H2 and L-428 Hodgkin Lymphoma Cells.Int J Mol Sci. 2020 Dec 31;22(1):343. doi: 10.3390/ijms22010343. Int J Mol Sci. 2020. PMID: 33396195 Free PMC article.
-
LHRH-conjugated lytic peptides directly target prostate cancer cells.Biochem Pharmacol. 2011 Jan 1;81(1):104-10. doi: 10.1016/j.bcp.2010.09.015. Epub 2010 Sep 30. Biochem Pharmacol. 2011. PMID: 20869347 Free PMC article.
-
Targeted destruction of follicle stimulating hormone receptor-positive cancer cells in vitro and in vivo by a lytic peptide Phor21-FSHβ conjugate.Mol Med. 2025 Jun 9;31(1):224. doi: 10.1186/s10020-025-01292-5. Mol Med. 2025. PMID: 40490708 Free PMC article.
-
Bee Venom Components as Therapeutic Tools against Prostate Cancer.Toxins (Basel). 2021 May 7;13(5):337. doi: 10.3390/toxins13050337. Toxins (Basel). 2021. PMID: 34067049 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous